Cherng Hua-Ren R, Sun Kai, Bentzen Soren M, Mishra Mark V
Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, Maryland.
Division of Biostatistics and Bioinformatics, University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland.
Int J Radiat Oncol Biol Phys. 2025 Feb 1;121(2):475-480. doi: 10.1016/j.ijrobp.2024.09.029. Epub 2024 Sep 25.
PURPOSE: We sought to estimate the conditional risk of development of neurocognitive function failure (NCFF) after whole brain radiation therapy (WBRT) for patients with brain metastases on NRG Oncology CC001. In addition, we aimed to determine if factors prognostic of NCFF at time of treatment remained relevant over time. METHODS AND MATERIALS: We performed a post hoc analysis of 518 patients enrolled on NRG-CC001 in which patients with brain metastases were randomly assigned to WBRT + memantine or hippocampal avoidant (HA-WBRT) + memantine. Life table method was used to calculate conditional monthly hazard rates and cumulative incidence was used to estimate rates of NCFF. Risk factors associated with NCFF were analyzed using cause-specific multivariable Cox proportional hazards modeling. RESULTS: The cumulative risk of development of NCFF by 6 months was 64.0% for the entire cohort. The greatest conditional monthly hazard rate of development of neurocognitive toxicity was 2 to 3 months postradiation (0.97; 95% CI, 0.85-1.10); this rate significantly declined and then plateaued to 0.036 (95% CI, 0-0.11) by 8 months posttreatment. For 2-month survivorship without cognitive failure, HA-WBRT (HR, 0.74; P = .033) and age ≤61 years (HR, 0.62; P = .003) continued to be protective against cognitive toxicity. In addition, conditional cumulative incidence of development of NCFF was significantly reduced with HA techniques for patients living ≥2 months free of cognitive dysfunction (P = .047). CONCLUSIONS: Our data highlight that the greatest risk of development of neurocognitive toxicity is within the first 3 months after treatment, and therefore strategies to mitigate toxicities should focus on this initial period. Moreover, the conditional risk of neurocognitive impairment significantly declines the longer patients live with preserved cognition. Importantly, these data can be used to inform patients on how their risks of development of NCFF can change over time.
目的:我们试图评估在NRG肿瘤学CC001研究中,脑转移瘤患者接受全脑放射治疗(WBRT)后发生神经认知功能衰竭(NCFF)的条件风险。此外,我们旨在确定治疗时NCFF的预后因素是否随时间推移仍具有相关性。 方法和材料:我们对NRG-CC001研究中入组的518例患者进行了事后分析,其中脑转移瘤患者被随机分配至WBRT + 美金刚或海马回避(HA-WBRT)+ 美金刚治疗组。采用生命表法计算条件月度风险率,并使用累积发病率来估计NCFF的发生率。使用特定病因多变量Cox比例风险模型分析与NCFF相关的风险因素。 结果:整个队列在6个月时发生NCFF的累积风险为64.0%。神经认知毒性发生的最大条件月度风险率出现在放疗后2至3个月(0.97;95%CI,0.85 - 1.10);该风险率显著下降,然后在治疗后8个月时趋于平稳,降至0.036(95%CI,0 - 0.11)。对于无认知功能衰竭存活2个月的患者,HA-WBRT(HR,0.74;P = 0.033)和年龄≤61岁(HR,0.62;P = 0.003)继续对认知毒性具有保护作用。此外,对于无认知功能障碍存活≥2个月的患者,HA技术显著降低了NCFF发生的条件累积发病率(P = .047)。 结论:我们的数据表明,神经认知毒性发生的最大风险在治疗后的前3个月内,因此减轻毒性的策略应聚焦于这一初始阶段。此外,患者认知功能保留的时间越长,神经认知障碍的条件风险显著下降。重要的是,这些数据可用于告知患者其发生NCFF的风险如何随时间变化。
Cochrane Database Syst Rev. 2025-6-19
J Parkinsons Dis. 2025-4-29
Cochrane Database Syst Rev. 2025-6-9